Protection by WR-2721 and WR-151327 against late effects of gamma rays and neutrons.
Two thiophosphoroate compounds WR-2721 and WR-151327 were assessed for their ability to modify the deleterious effects (life shortening and carcinogenesis) of fission-spectrum neutrons (kerma-weighted mean energy of 0.85 MeV) or gamma rays on B6CF1 hybrid mice.  Male and female mice, 200 of each sex per experimental group, were irradiated individually at 110 days of age.  Radioprotectors (400 mg/kg of WR-2721 or 580 mg/kg of WR-151327) were administered intraperitoneally 30 min prior to irradiation.  Neutron doses were 10 cGy or 40 cGy and gamma ray doses were 206 cGy or 417 cGy.  Animals were housed five to a cage; cage locations in the holding rooms were randomized by computer.  Animals were checked daily and all deceased animals were necropsied.  WR-2721 afforded protection against both neutron- and gamma-ray-induced carcinogenesis and subsequent life shortening. Cumulative survival curves for unirradiated mice of either sex were unaffectecd by protectors.  WR-2721 protected irradiated groups against life shortening by approximately 10 cGy of neutrons or 100 cGy of gamma rays.  WR-151327 was as effective as WR-2721 against neutron irradiation.
Grdina
D J
DJ
Biological and Medical Research Division, Argonne National Laboratory, Argonne, Illinois 60439, USA.
Garnes
B A
BA
Nagy
B
B
D004999:Amifostine / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D005260:Female; D005720:Gamma Rays / Q000009:adverse effects*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D016296:Mutagenesis; D009381:Neoplasms, Radiation-Induced / Q000188:drug therapy / Q000517:prevention & control; D009502:Neutrons / Q000009:adverse effects*; D009946:Organothiophosphorus Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D011829:Radiation Dosage; D011833:Radiation Injuries, Experimental / Q000188:drug therapy / Q000401:mortality* / Q000517:prevention & control; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D012737:Sex Factors; D015996:Survival Rate; D013997:Time Factors
D009946:Organothiophosphorus Compounds; D011837:Radiation-Protective Agents; C048392:WR 151327; D004999:Amifostine